... active dose有效剂量 active placebo treatment阳性安慰剂治疗 active treatment concurrent control阳性药物并行对照 ...
基于1个网页-相关网页
We performed a double-blind, multicenter study, comparing MMX mesalamine vs placebo for the treatment of active ulcerative colitis.
我们进行了一项双盲，多中心研究，比较了美沙美拉明与美沙酮对安慰剂治疗活动性溃疡性结肠炎的疗效。
The median time to relapse after stopping treatment was about 38 days in both the patients who switched to placebo and in the active treatment group.
包括改服安慰剂和主动治疗组的所有患者在内，在停止治疗后中位复发时间为38天。
At 52 weeks, all of the active treatment groups showed significant reduction in LDL cholesterol from baseline and compared to placebo. The treatment was also well tolerated.
在治疗的第52周，所有使用阿托伐他汀治疗的患者，其低密度脂蛋白水平不管是基线水平还是与安慰剂比较都显著降低。
应用推荐